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Synopsis
High doses of Ang II receptor (AT1R) blockers (ARBs) are renoprotective in diabetes. Underlying mechanisms remain
unclear. We evaluated whether high/ultra-high doses of candesartan (ARB) up-regulate angiotensin-converting enzyme
2 (ACE2)/Ang II type 2 receptor (AT2R)/Mas receptor [protective axis of the of the renin–angiotensin system (RAS)] in
diabetic mice. Systolic blood pressure (SBP), albuminuria and expression/activity of RAS components were assessed
in diabetic db/db and control db/ + mice treated with increasing candesartan doses (intermediate, 1 mg/kg/d; high,
5 mg/kg/d; ultra-high, 25 and 75 mg/kg/d; 4 weeks). Lower doses candesartan did not influence SBP, but ultra-high
doses reduced SBP in both groups. Plasma glucose and albuminuria were increased in db/db compared with db/ +
mice. In diabetic mice treated with intermediate dose candesartan, renal tubular damage and albuminuria were
ameliorated and expression of ACE2, AT2R and Mas and activity of ACE2 were increased, effects associated with
reduced ERK1/2 phosphorylation, decreased fibrosis and renal protection. Ultra-high doses did not influence the
ACE2/AT2R/Mas axis and promoted renal injury with increased renal ERK1/2 activation and exaggerated fibronectin
expression in db/db mice. Our study demonstrates dose-related effects of candesartan in diabetic nephropathy:
intermediate–high dose candesartan is renoprotective, whereas ultra-high dose candesartan induces renal damage.
Molecular processes associated with these effects involve differential modulation of the ACE2/AT2R/Mas axis:
intermediate–high dose candesartan up-regulating RAS protective components and attenuating pro-fibrotic processes,
and ultra-high doses having opposite effects. These findings suggest novel mechanisms through the protective RAS
axis, whereby candesartan may ameliorate diabetic nephropathy. Our findings also highlight potential injurious renal
effects of ultra-high dose candesartan in diabetes.
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INTRODUCTION
Major morbidities associated with diabetes include adverse car-
diovascular events and nephropathy, a leading cause of end-stage
renal disease [1]. The renin–angiotensin system (RAS) plays a
pivotal role in the pathophysiology of cardiovascular and kid-
ney dysfunction. This is supported by extensive experimental
and clinical data demonstrating that RAS inhibition, besides re-
ducing blood pressure, slows progression of proteinuric kidney
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disease and protects against target organ damage [2–14]. The
RAS, in its classic definition, is known as an endocrine system
that exerts its actions through the effector peptide angiotensin
II (Ang II). Besides being a potent vasoactive peptide and regu-
lator of salt and volume homoeostasis, Ang II, through its type 1
receptor (AT1R) promotes target organ damage by activating
proinflammatory, pro-fibrotic and mitogenic signalling pathways
[12–14]. Other components of the RAS may counteract these
Ang II/AT1R damaging actions, such as signalling through the
Ang II type 2 receptor (AT2R). In addition Ang-(1–7), produced
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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by angiotensin-converting enzyme 2 (ACE2), and which signals
through the Mas receptor, has been associated with cardiovascu-
lar and renal protection, in part, by antagonizing Ang II/AT1R
actions [15–19].
Growing evidence indicates that ACE inhibitors and AT1R
blockers (ARBs) protect against diabetic kidney injury inde-
pendent of their haemodynamic effects [2,3]. Clinical studies
have shown beneficial effects of ACE inhibitors and ARBs in
delaying the onset of microalbuminuria in patients with type 2
diabetes [20–22]. Combined therapy with ACE inhibitors and
ARBs decreases proteinuria and further slows the progression of
glomerular filtration rate decline [22–26]. However, these obser-
vations have been challenged in light of new findings from large
clinical studies [27,28]. Patients exhibited worsening of renal out-
comes with combined ACE inhibitors and ARBs, including an
increased risk of hyperkalaemia and acute kidney injury [27,28].
On the other hand, significant renal protection by ARB mono-
therapy was observed when patients with diabetes were treated
with higher doses than those recommended as antihypertensive
treatment [29–33]. The beneficial effects of high dose ARBs have
been attributed, in part, to reduction in glomerular capillary hy-
drostatic pressure, decreased expression of proinflammatory me-
diators and reduced oxidative stress [33,34]. However molecular
mechanisms underlying these phenomena are unclear and it is un-
known whether high-dose ARBs influence the ‘protective’ com-
ponents of the RAS, namely AT2R, ACE2 and Ang-(1–7)/Mas.
Since proteinuria predicts adverse renal outcomes and con-
versely its reduction is associated with improved kidney function
[35], we evaluated whether the AT1R antagonist candesartan, in
an intermediate- to ultra-high dose range, reduces renal injury
in db/db mice, a model of type 2 diabetes. We also tested whether
increasing doses of candesartan up-regulates renal AT2R, ACE2
and Ang-(1–7)/Mas expression/activity.
MATERIALS AND METHODS
See supplementary text for extended methods section.
Animals
Seven-week-old male Leprdb/Lepr+ (db/ + ) and Leprdb/Leprdb
(db/db) mice (from Jackson Laboratories) were treated for
4 weeks (by subcutaneous injection) with increasing doses
of candesartan (AstraZeneca): intermediate (1 mg/kg/d), high
(5 mg/kg/d) and ultra-high (25 and 75 mg/kg/d). Vehicle-treated
db/db and db/ + mice were used as control groups. Systolic blood
pressure (SBP) was measured by tail-cuff plethysmography.
Urinary albumin and creatinine excretion
Spot urine was collected for assessment of albumin (μg/ml) and
creatinine (mg/ml). Results were expressed as albumin:creatinine
ratio (ACR, μg/mg).
Western blot
Total protein was extracted from kidney cortex and probed for
AT2R, Mas, ACE2, ERK1/2, p38MAPK, JNK, plasminogen ac-
tivator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1
(VCAM-1) and osteopontin (OPN) by western blotting.
Kidney staining and morphometry
Fixed paraffin-embedded kidney tissues were stained with
haematoxylin & eosin and periodic acid–Schiff (PAS) staining.
ACE and ACE2 enzymatic activity
ACE and ACE2 enzymatic activity in plasma and kidney cortex
homogenates were determined following incubations with the
respective synthetic specific substrates.
AT1R expression by quantitative real-time PCR
Total RNA was extracted from kidney cortex. Real-time PCR
was used to determine the expression levels of AT1R mRNA.
Statistical analysis
Data are presented as means +− S.E.M. Groups were compared
using one-way ANOVA with Tukey correction to compensate for
multiple testing procedures and two-way ANOVA with Bonfer-
roni post-hoc test, as appropriate. P < 0.05 was significant.
RESULTS
Animal data and plasma analyses
Body mass and relative kidney mass were greater in db/db
mice compared with db/ + mice and were unaffected by can-
desartan treatment (Supplementary Table S1). Plasma biochem-
istry is summarized in Table 1. In vehicle-treated groups plasma
glucose, phosphate and creatinine levels were higher in db/db
mice compared with db/ + mice, without any effect of treat-
ment. Candesartan at 25 and 75 mg/kg/d increased plasma phos-
phate and creatinine in db/ + mice compared with vehicle-treated
db/ + counterparts. In vehicle-treated groups blood urea nitro-
gen (BUN) levels were similar in db/db mice and db/ + mice.
BUN progressively increased in both experimental groups with
candesartan treatment.
Systolic blood pressure
Figure 1 shows SBP in mice at the study end point. At 4 weeks of
treatment, 1 mg/kg/d candesartan had no effect on SBP in db/ +
or db/db mice. A reduction in SBP was observed with 5 mg/kg/d
candesartan after 4 weeks treatment in the db/ + mice com-
pared with vehicle-treated db/ + mice. The hypotensive response
was similar in the db/ + and db/db mice at 25 and 75 mg/kg/d
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Figure 1 Ultra-high dose of candesartan reduce SBP in db/+ and
db/db mice
End point SBP in db/ + and db/db mice treated with subcu-
taneous injections of vehicle or candesartan at 1 mg/kg/d, 5 mg/kg/d,
25 mg/kg/d, 75 mg/kg/d for 4 weeks. Results are mean +− S.E.M. of
seven mice. *P< 0.05, candesartan-treated compared with counterpart
vehicle-treated mice.
candesartan. Time course of decrease in SBP is shown in Sup-
plementary Figure S1. Candesartan evoked a gradual decrease in
SBP starting earlier and with lower doses in db/ + mice. Can-
desartan at 75 mg/kg/d induced a similar time course of decrease
in SBP in both experimental groups. No differences were ob-
served in SBP between vehicle-treated db/ + and db/db groups.
Urinary albumin excretion
The urinary ACR, an index of kidney injury, was increased in
db/db mice at baseline compared with db/ + mice (Figure 2). In
the vehicle-treated db/db group, the ACR remained elevated for
the duration of the study (Supplementary Figure S2). Candesartan
at 1 mg/kg/d (Figure 2a), 5 mg/kg/d (Figure 2b) and 25 mg/kg/d
(Figure 2c), reduced albuminuria. Higher doses of candesartan
had no effect on ACR (Figure 2d).
Effects of candesartan on kidney histology
Histological features of kidney structure in db/db and db/ + mice
are presented in Figure 3. db/db mice showed increased glom-
erular, mesangial and capillary cross-sectional area, compared
with db/ + mice, effects that were reduced by candesartan (Fig-
ures 3a–3c). In db/ + mice, candesartan ultra-high doses sig-
nificantly reduced glomerular and capillary cross-sectional area
and increased mesangial cross-sectional area. db/db and db/ +
mice did not exhibit differences in mesangial cell number per
glomerular section (Supplementary Figure S3). Features of neph-
ropathy are shown in Figure 4. In vehicle-treated db/db mice,
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Figure 2 Intermediate to high, but not ultra-high, dose of candesartan ameliorates albuminuria in db/db mice
Urinary albumin was assessed in db/ + and db/db mice at baseline (0 time point) and following 2 and 4 weeks of vehicle
or candesartan daily subcutaneous injections. Mice were treated with vehicle or candesartan at 1 mg/kg/d (a); 5 mg/kg/d
(b); 25 mg/kg/d (c); 75 mg/kg/d (d). Albuminuria was expressed as albumin (μg/ml):creatinine (mg/ml) ratio. Results
are presented as mean +− S.E.M. of 5–7 mice in each group. *P< 0.05 compared with vehicle-treated db/ + ; **P< 0.05
candesartan-treated db/db compared with db/ + of corresponding week; †P< 0.05 candesartan-treated db/db compared
with vehicle-treated db/db.
distal tubules showed dystrophic lesions with areas of complete
desquamation and necrosis (Figure 4b). Only 1 mg/kg/d can-
desartan was effective in decreasing distal tubular damage in
db/db mice (Figures 4c–4e). Candesartan induced cortical tu-
bulointerstitial nephritis in a dose-dependent manner in both
groups (Figure 4f). Focal tubular basophilia, at S1–S2 segments
of the proximal tubules of the outer cortex, was predominant in
the subcapsular zone (Figures 4g and 4h). Cell infiltrates com-
prised rare neutrophils and lymphocytes with predominant mac-
rophages. There was no evidence of ischemic tubular injury as
there were no signs of epithelial necrosis of the straight segments
of the proximal tubules and the ascending limbs of the loops of
Henle.
Effects of candesartan on RAS receptor expression
in kidney cortex
In vehicle-treated groups, db/db mice displayed increased ex-
pression of AT2R compared with db/ + mice (Figure 5a). In
db/db mice, candesartan (1–25 mg/kg/d) produced an additional
increase in AT2R expression. In db/ + mice, an increase in AT2R
expression was observed only at ultra-high candesartan doses.
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Figure 3 Increasing doses of candesartan reduce glomerular area enlargement in the kidney cortex of db/db mice
Kidney morphometry. Glomerular (a), mesangial (b) and capillary (c) cross-sectional area were evaluated in kidney cortex
from db/ + and db/db mice treated with vehicle or candesartan 1 mg/kg/d, 5 mg/kg/d, 25 mg/kg/d, 75 mg/kg/d.
*P< 0.05 compared with vehicle-treated db/ + ; †P< 0.05 candesartan-treated db/db compared with vehicle-treated
db/db.
Mas receptor expression was similar in vehicle-treated db/ + and
db/db mice (Figure 5b). Treatment with 1 mg/kg/d candesartan
increased expression of Mas receptor in both groups.
AT1R expression was studied at the transcript level, due to
the fact that commercial AT1R antibodies are non-specific [36].
Kidney AT1R mRNA expression was similar in db/ + and db/db
mice treated with vehicle (Supplementary Figure S4). In db/db
mice, candesartan at 1 and 75 mg/kg/d decreased mRNA expres-
sion of AT1R, whereas no effects were observed at other doses.
Candesartan did not affect AT1R mRNA expression in db/ +
mice.
Effects of candesartan on expression and activity
of ACE and ACE2
As shown in Figure 6(a), ACE expression in kidney cor-
tex was lower in all db/db groups compared with vehicle-
and candesartan-treated counterparts. Figure 6(b) shows
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Figure 4 Candesartan (1 mg/kg/d) improves tubular damage in db/db mice
Mice were daily treated with subcutaneous injections of vehicle or candesartan (1, 5, 25 or 75 mg/kg/d) for 4 weeks.
Representative photographs of PAS-stained tubules and interstitium (a–d, g and h). Bar graphs: scores for tubular damage
in db/db mice (e) and tubulointerstitial nephritis in db/ + and db/db mice (f). Arrows, indicate cell infiltrates. *P< 0.05
compared with vehicle-treated counterpart.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
Candesartan, diabetic nephropathy and the protective axis of the renin–angiotensin system
Figure 5 Candesartan modulates expression of RAS receptors in kidney cortex from db/db mice
Protein expression of AT2R (a) and Mas receptor (b) in kidney cortex from db/ + and db/db mice treated with vehicle
or candesartan (1, 5, 25 or 75 mg/kg/d). Side panels, representative immunoblots of AT2R, Mas receptor and β -actin.
Results are presented as mean +− S.E.M. of 5–7 mice. *P< 0.05 compared with vehicle-treated db/ + ; **P< 0.05
db/db compared with db/ + of corresponding candesartan dose; †P< 0.05 candesartan-treated db/db compared with
vehicle-treated db/db.
similar ACE2 expression in kidney from vehicle-treated db/ +
and db/db mice. At 1 mg/kg/d, candesartan increased ACE2 ex-
pression in db/db mice compared with vehicle-treated db/db
mice. Candesartan at ultra-high dose, reduced expression of
ACE and ACE2 in db/ + mice compared with vehicle-treated
counterparts.
Enzymatic activity of ACE and ACE2 was assessed in plasma
and kidney cortex. Vehicle-treated db/db mice displayed lower
ACE activity in plasma (Figure 7a) and kidney cortex (Figure 7b)
compared with db/ + mice in basal conditions. Candesartan did
not affect ACE activity in plasma or kidney from db/db mice.
Plasma ACE activity was increased with higher doses of can-
desartan (Figure 7a) whereas kidney ACE2 activity was reduced
with treatment (Figure 7b). ACE2 activity in plasma (Figure 7c)
and kidney (Figure 7d) was similar in vehicle-treated db/ + and
db/db mice. In db/db mice, candesartan at 5 and 25 mg/kg/d
increased plasma ACE2 activity compared with vehicle-treated
counterparts. In db/ + mice candesartan had no effect on plasma
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Figure 6 Intermediate dose of candesartan increases expression of ACE2 in kidney cortex from db/db mice
Protein expression of ACE (a) and ACE2 (b) in kidney cortex from db/ + and db/db mice treated with vehicle or candesartan
(1, 5, 25 or 75 mg/kg/d). Side panels, representative immunoblots of ACE, ACE 2 and β -actin. Results are presented as
mean +− S.E.M. of 5–7 mice. *P< 0.05 compared with vehicle-treated db/ + ; **P< 0.05 db/db compared with db/ + of
corresponding candesartan dose; †P< 0.05 candesartan-treated db/db compared with vehicle-treated db/db.
ACE2 activity, but reduced activity in kidney cortex at high and
ultra-high doses.
Effects of candesartan on renal MAPK
phosphorylation
Phosphorylation of renal ERK1/2 was increased in vehicle-
treated db/db mice compared with controls (Figure 8). Can-
desartan at low doses, decreased ERK1/2 phosphorylation in
db/db mice, whereas at ultra-high dose, opposite effects were ob-
served. Similar responses were evident in db/ + mice. p38MAPK
phosphorylation was increased in vehicle-treated db/db com-
pared with db/ + mice (Supplementary Figure S5a). Can-
desartan, 25 mg/kg/d, amplified p38MAPK phosphorylation in
db/db mice, whereas in db/ + mice, 75 mg/kg/d candesartan
increased p38MAPK phosphorylation. In basal conditions, the
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Figure 7 Intermediate dose of candesartan increases renal activity of ACE2, but not ACE, in db/db mice
Enzymatic activity of ACE (a, b) and ACE2 (c, d) in plasma and kidney cortex from db/ + and db/db mice treated with
vehicle or candesartan (1, 5, 25 or 75 mg/kg/d). Results are presented as mean +− S.E.M. of 5–7 mice. *P< 0.05
compared with vehicle-treated db/ + ; **P< 0.05 db/db compared with db/ + of corresponding candesartan dose;
†P< 0.05 candesartan-treated db/db compared with vehicle-treated db/db.
magnitude of JNK phosphorylation was similar in db/ + and
db/db mice (Supplementary Figure S5b). Treatment with increas-
ing doses of candesartan was associated with an increase in JNK
phosphorylation in db/db mice.
Candesartan effects on renal pro-fibrotic and
pro-inflammatory markers
Renal fibronectin expression was increased in vehicle-treated
db/db compared with db/ + mice (Figure 9). Candesartan at
1 mg/kg/d reduced fibronectin content in db/db to similar levels
observed in db/ + mice. However, at higher doses, candesartan
increased fibronectin content in both strains. PAI-1 content was
lower in db/db compared with db/ + mice in the vehicle-treated
groups (Supplementary Figure S6a). Candesartan at 1 mg/kg/d
increased PAI-1 expression in db/db mice. Kidney cortex from
db/db mice displayed increased levels of VCAM-1 (Supple-
mentary Figure S6b). Expression of the adhesion molecule was
reduced by 75 mg/kg/d candesartan in both strains. No differ-
ences were detected in OPN expression between vehicle-treated
groups (Supplementary Figure S6c). At 25 mg/kg/d candesartan
increased OPN expression in db/db mice.
DISCUSSION
Clinical studies demonstrated that in patients with persistent pro-
teinuria, candesartan at doses four and eight times higher than the
recommended daily dose of 16 mg for blood pressure lowering
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Figure 8 High and ultra-high doses of candesartan increase renal ERK1/2 phosphorylation in db/db mice
Phosphorylation levels of ERK1/2 in kidney cortex from db/ + and db/db mice treated with vehicle or candesartan (1, 5,
25 or 75 mg/kg/d). Side panels, representative immunoblots of ERK1/2 [Thr202/Tyr204] and β -actin. Results are presented
as mean +− S.E.M. of 5–7 mice. *P< 0.05 compared with vehicle-treated db/ + ; **P< 0.05 db/db compared with db/ +
of corresponding candesartan dose; †P< 0.05 candesartan-treated db/db compared with vehicle-treated db/db.
Figure 9 Candesartan modulates expression of pro-fibrotic and pro-inflammatory markers in kidney cortex from db/db
mice
Protein expression of fibronectin in kidney cortex from db/ + and db/db mice treated with vehicle or candesartan (1,
5, 25 or 75 mg/kg/d). Side panels, representative immunoblots of fibronectin and β -actin. Results are presented as
mean +− S.E.M. of 5–7 mice. *P< 0.05 compared with vehicle-treated db/ + ; **P< 0.05 db/db compared with db/ + of
corresponding candesartan dose; †P< 0.05 candesartan-treated db/db compared with vehicle-treated db/db.
was associated with a significant additional reduction (>33 %)
in proteinuria [8,22,26]. Accordingly, doses greater than that ori-
ginally recommended for hypertension have been suggested in
the treatment of proteinuria [29–33]. Despite the encouraging
findings, mechanisms underlying the added benefit of supra-
high doses of candesartan remain unclear. Here we sought to
address this by studying the putative role of the protective axis
of the RAS, by focusing on ACE2, AT2R and Mas, in a mouse
model of diabetic nephropathy treated with increasing doses of
candesartan, from intermediate (1 mg/kg/d) to ultra-high doses
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(75 mg/kg/d). Major findings from our study demonstrate that in
db/db diabetic mice, candesartan at intermediate to high doses
(1) reduced albuminuria, (2) prevented renal injury evidenced
by decreased mesangial expansion and glomerular hypertrophy,
(3) reduced renal fibrosis and ERK1/2 phosphorylation, (4) in-
creased renal expression of AT2R and Mas and (5) increased
ACE2 expression/activity. Ultra-high doses of candesartan failed
to protect against renal injury or albuminuria and did not influ-
ence ACE2, AT2R or Mas, but increased activation of MAPK
and pro-fibrotic signalling in db/db mice. Our findings indicate
that at intermediate-high doses, candesartan has renoprotective
effects with associated up-regulation of the protective axis of
the RAS, whereas at ultra-high doses, candesartan worsens renal
damage and albuminuria without positively affecting on ACE2,
AT2R and Mas in mice with diabetic nephropathy.
The RAS is an important therapeutic target for effective blood
pressure lowering and for protection from progressive kidney
damage in diabetic and nondiabetic kidney disease [2–14]. ARBs
prevent or delay progression to end-stage renal disease independ-
ently of reductions in blood pressure [2, 3, 29–33]. This is par-
ticularly evident at high or ultra-high doses, where renoprotect-
ive effects of candesartan, and other ARBs, when administered
at doses higher than those used in the treatment of hyperten-
sion, had added benefit without further affecting blood pressure
[29–33]. ARBs at recommended blood pressure-lowering doses
ameliorate kidney injury, glomerulosclerosis, kidney hypertrophy
and prevent interstitial fibrosis, most likely by inhibiting Ang II
signalling through the AT1R and by improving Ang II hemo-
dynamic actions [6,8]. Mechanisms underlying the added blood
pressure-independent benefit of high dose ARBs remains unclear
but exposing the protective AT2R/Mas pathway, when AT1R is
completely blocked, may be important. Previous studies demon-
strated that ultra-high dose candesartan ameliorated renal injury
and proteinuria in SHR through an anti-inflammatory mechan-
ism by inhibiting NFκB signalling and chemokine production
[33]. However, it is unclear whether this is due to AT1R inhibi-
tion or activation of AT2R and Mas. We suggest here that high
dose candesartan exerts beneficial actions by up-regulating the
counter-regulatory axis of Ang II–AT1R.
Albuminuria, an early and sensitive marker for progressive
renal dysfunction, was a primary outcome in our study. Treatment
with intermediate and high doses of candesartan reduced albu-
minuria indicating improved renal function. However at ultra-
high doses, there was a progressive dose-dependent loss of the
beneficial effect as evidenced in the db/db mice, which exhib-
ited persistent albuminuria, and increased plasma creatinine and
BUN/creatinine. The worsening of kidney function at ultra-high
doses was associated with a significant decrease in blood pressure
and it may be possible that the adverse renal effects at 75 mg/kg/d
relate, in part, to significant blood pressure lowering and possible
renal hypoperfusion. These effects might be related to excessive
RAS blockade, as adverse events have been reported with com-
bination therapy with ACE inhibitor and ARB in patients with
diabetic nephropathy [28].
Diabetic db/db mice display many pathologic features at the
functional and structural levels that are associated with the early
phases of diabetic nephropathy, including albuminuria, mesangial
expansion, reduction in glomerular cell number, as well as later
changes, such as tubular damage and tubulointerstitial nephritis,
effects that may be ameliorated by the candesartan treatment.
Indeed, renoprotection with decrease in proteinuria have been
reported in animal studies with higher doses of ARBs [32,33].
Candesartan at all doses was effective in normalizing mesangial
expansion. Only the intermediate dose of candesartan showed
recovery of tubular damage. These data suggest that intermedi-
ate dose of candesartan, which is still higher than the standard
for blood pressure control, is beneficial for preventing the pro-
gression of diabetic nephropathy. However, ultra-high doses of
candesartan induced more severe glomerular and tubular damage,
effects that were exacerbated in db/ + non-diabetic mice. Lesions
observed with ultra-high doses of candesartan are frequently en-
countered manifestations of drug-related injury, particularly in
repeat-dose toxicity studies [37]. These severe structural changes
were associated with functional impairment and probably relate
to low blood pressure and possible hypoperfusion and ischemia.
To explore possible molecular mechanisms whereby can-
desartan induces renoprotective effects beyond AT1R block-
ade, we investigated the protective axis of the RAS, compris-
ing ACE2/Ang-(1–7)/Mas receptor [15–19,38–40]. ACE2, a new
member of the ACE family, predominantly metabolizes Ang II
to generate Ang-(1–7). Ang-(1–7), in general, opposes actions
of Ang II. By acting through the Mas receptor, Ang-(1–7) pro-
motes vasodilatation and inhibits proliferation, inflammation and
hypertrophy. Our study demonstrates that candesartan at inter-
mediate to high doses increases ACE2 expression and activity in
plasma and kidney. It is well-known that the levels of Ang II in-
crease when the AT1R is blocked [41]. Thus, with ARBs, there is
incomplete suppression of Ang II. It is possible that ACE2 amp-
lification with intermediate to high doses of candesartan could
be more effective by cleaving Ang II into Ang-(1–7), which fur-
ther counteracts the actions of the AT1R activation. Thereby,
ARB dose increment may provide organ protection beyond what
is already achieved by the current blockade of AT1R. The
effects of candesartan on ACE2 overexpression are associated
with modulation of other RAS elements. The increase in AT2R
and Mas receptor expression was combined with reduction in
AT1R gene expression. Unexpectedly, kidney cortex from db/db
mice displayed decreased ACE activity and expression. This
could explain why db/db mice have normal levels of blood pres-
sure, despite the dramatic vascular endothelial dysfunction ex-
tensively described in type 2 diabetes [42,43]. Nevertheless, can-
desartan did not affect ACE activity or expression. Overall these
findings corroborate the notion that intermediate to high doses
of candesartan may influence the protective components of the
RAS to mediate the ARB blood pressure-lowering-independent
renoprotective effects.
Activation of MAPKs is a pivotal signalling pathway involved
in pro-fibrotic, pro-inflammatory and mitogenic effects in the kid-
ney [12,13]. Previous reports demonstrated increased activation
of MAPK in db/db [43,44], similar to our findings here. Can-
desartan variably attenuated activation of MAPKs, but at ultra-
high doses, MAPK phosphorylation was amplified. This response
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is in line with the augmented deleterious renal functional and
structural effects that we observed with ultra-high candesartan
doses. One of the many processes influenced by MAPKs is in-
flammation, which is closely linked to renal fibrosis and complic-
ations of diabetic nephropathy [45–50]. The increased fibronectin
protein content in kidney cortex from db/db mice was suppressed
by candesartan at intermediate dose, indicating that at this dose
candesartan has anti-fibrotic actions. Candesartan at 75 mg/kg/d
mg was associated with increased expression of fibronectin, but
not pro-inflammatory molecules VCAM-1, PAI-1 and OPN in
db/db mice.
In summary, intermediate to high doses of candesartan ameli-
orate progression of nephropathy in db/db mice with associated
up-regulation of the protective arm of the RAS. The present
study provides new insights into some putative mechanisms,
specifically activation of the ACE2/AT2R/Mas axis, whereby
intermediate-high dose candesartan protect against diabetic neph-
ropathy independently of blood pressure lowering. However at
ultra-high doses candesartan loses its renoprotective properties
and seems to promote more harm than benefit. This may relate
to significant blood pressure lowering and possible renal hypop-
erfusion. Our findings may need to be considered in the clinical
context where higher doses of ARBs are increasingly being used
to treat diabetic nephropathy.
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